Goldman Sachs
RCEL icon

Goldman Sachs’s Avita Medical RCEL Stock Holding History

Goldman Sachs’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Sell
76,737
-23,108
-23% -$99.7K ﹤0.01% 5983
2026
Q1 		$369K Buy
99,845
+19,232
+24% +$80.7K ﹤0.01% 5777
2025
Q4 		$278K Sell
80,613
-36,232
-31% -$145K ﹤0.01% 5902
2025
Q3 		$597K Buy
116,845
+23,190
+25% +$121K ﹤0.01% 5401
2025
Q2 		$495K Sell
93,655
-73,384
-44% -$534K ﹤0.01% 5164
2025
Q1 		$1.36M Sell
167,039
-8,440
-5% -$78.9K ﹤0.01% 4464
2024
Q4 		$2.25M Buy
175,479
+90,162
+106% +$1.06M ﹤0.01% 4175
2024
Q3 		$915K Sell
85,317
-8,189
-9% -$76.9K ﹤0.01% 4695
2024
Q2 		$741K Buy
93,506
+12,601
+16% +$120K ﹤0.01% 4603
2024
Q1 		$1.3M Buy
80,905
+53,137
+191% +$860K ﹤0.01% 4165
2023
Q4 		$381K Buy
27,768
+5,254
+23% +$60.2K ﹤0.01% 4886
2023
Q3 		$329K Sell
22,514
-10,173
-31% -$172K ﹤0.01% 4851
2023
Q2 		$556K Sell
32,687
-44,108
-57% -$647K ﹤0.01% 4689
2023
Q1 		$1.07M Buy
+76,795
New +$817K ﹤0.01% 4336
2022
Q3 		– Sell
-18,273
Closed -$87K – 6492
2022
Q2 		$87K Sell
18,273
-6,718
-27% -$41.5K ﹤0.01% 5906
2022
Q1 		$212K Sell
24,991
-56,589
-69% -$522K ﹤0.01% 5851
2021
Q4 		$978K Buy
81,580
+71,115
+680% +$1.08M ﹤0.01% 4855
2021
Q3 		$185K Sell
10,465
-134,608
-93% -$2.54M ﹤0.01% 5751
2021
Q2 		$2.98M Buy
145,073
+46,495
+47% +$916K ﹤0.01% 3834
2021
Q1 		$1.95M Buy
+98,578
New +$2.29M ﹤0.01% 4009

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's RCEL Position: Q2 2026 in Review

Goldman Sachs reduced its Avita Medical (RCEL) stake by 23% in Q2 2026, selling an estimated $99.7K and leaving 76,737 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #5983.

Goldman Sachs first reported a position in RCEL in Q1 2021 and has held it in 20 quarters since. The position peaked at $2.98M in Q2 2021. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Goldman Sachs held 76,737 shares of Avita Medical worth $317K as of Q2 2026.
  • Goldman Sachs sold 23,108 Avita Medical shares in Q2 2026, an estimated $99.7K.
  • Avita Medical made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5983 holding.
  • Goldman Sachs first reported a position in Avita Medical in Q1 2021 and has held it in 20 quarters since.
  • Goldman Sachs's Avita Medical position peaked at $2.98M in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.